TransMedics CEO trust buys TMDX shares in market

TransMedics Group’s President and CEO Waleed H. Hassanein, through the Waleed H. Hassanein Revocable Trust, reported open‑market purchases of the company’s common stock.

Rhea-AI Filing Summary

TransMedics Group’s President and CEO Waleed H. Hassanein, through the Waleed H. Hassanein Revocable Trust, reported open‑market purchases of the company’s common stock. On August 6, 2025, the trust bought 8,400 shares at a weighted average price of $118.68.

On August 7, 2025, the trust made additional open‑market purchases of 6,617 shares at a weighted average price of $116.08 and 1,858 shares at a weighted average price of $116.85. After these transactions, the trust indirectly held 486,234 shares, and Hassanein directly held 121,424 shares.

Insider Trade Summary

Net Buyer: 16,875 shares

Net Buy 4 txns

Insider Hassanein Waleed H

Role President & CEO

Bought 16,875 shs ($1.98M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	6,617	$116.08	$768K
Purchase	Common Stock	1,858	$116.85	$217K
Purchase	Common Stock	8,400	$118.68	$997K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 486,234 shares (Indirect, By the Waleed H. Hassanein Revocable Trust); Common Stock — 121,424 shares (Direct)

Footnotes (3)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $118.50 to $118.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
2. F2. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $115.60 to $116.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
3. F3. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $116.62 to $117.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TransMedics (TMDX) report for Waleed Hassanein?

The filing shows open‑market purchases of TransMedics common stock by the Waleed H. Hassanein Revocable Trust. These occurred on August 6–7, 2025, and are reported as indirect ownership associated with President and CEO Waleed H. Hassanein.

How many TransMedics (TMDX) shares did the Hassanein trust buy and at what prices?

The revocable trust bought 8,400 shares at a weighted average price of $118.68, 6,617 shares at $116.08, and 1,858 shares at $116.85. Each reported price reflects a weighted average over multiple trades within disclosed price ranges.

How many TransMedics (TMDX) shares does Waleed Hassanein beneficially own after these trades?

After the reported purchases, the Waleed H. Hassanein Revocable Trust indirectly held 486,234 shares of TransMedics common stock. Separately, Waleed Hassanein is shown as directly owning 121,424 shares, according to the beneficial ownership figures in the filing.

Were the TransMedics (TMDX) insider transactions direct or through a trust?

All reported purchases were made indirectly through the Waleed H. Hassanein Revocable Trust. The filing identifies these as indirect holdings, while a separate line item lists 121,424 shares held under Waleed Hassanein’s direct ownership.

What does the weighted average price disclosure mean in the TransMedics (TMDX) Form 4?

Each transaction’s price is disclosed as a weighted average across multiple trades within a stated range. The filer commits to provide, upon request, detailed information on the number of shares purchased at each individual price inside those ranges.

What role does Waleed Hassanein hold at TransMedics (TMDX) in this Form 4?

The reporting person, Waleed H. Hassanein, is identified as both a Director and the company’s President & CEO. The Form 4 links his executive and board roles to the reported indirect purchases through the Waleed H. Hassanein Revocable Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/08/2025 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hassanein Waleed H

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MA 01810

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		P		8,400	A	$118.68(1)	477,759	I	By the Waleed H. Hassanein Revocable Trust
Common Stock	08/07/2025		P		6,617	A	$116.08(2)	484,376	I	By the Waleed H. Hassanein Revocable Trust
Common Stock	08/07/2025		P		1,858	A	$116.85(3)	486,234	I	By the Waleed H. Hassanein Revocable Trust
Common Stock								121,424	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $118.50 to $118.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

2. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $115.60 to $116.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

3. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $116.62 to $117.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.